Wells Fargo & Company Dyne Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DYN
# of Institutions
203Shares Held
105MCall Options Held
82.7KPut Options Held
24.8K-
Atlas Venture Life Science Advisors, LLC8.02MShares$235 Million37.7% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$230 Million40.83% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$216 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.39MShares$187 Million3.76% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$177 Million3.22% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.52B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...